214 related articles for article (PubMed ID: 33680936)
1. Detection of Circulating Tumor Cells in Resectable Pancreatic Ductal Adenocarcinoma: A Prospective Evaluation as a Prognostic Marker.
Song BG; Kwon W; Kim H; Lee EM; Han YM; Kim H; Byun Y; Lee KB; Lee KH; Lee KT; Lee JK; Jang JY; Park JK
Front Oncol; 2020; 10():616440. PubMed ID: 33680936
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma.
Kim H; Heo CM; Oh J; Chung HH; Lee EM; Park J; Lee SH; Lee KH; Lee KT; Lee JK; Cho YK; Park JK
Transl Oncol; 2022 Feb; 16():101321. PubMed ID: 34954457
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Implications of Portal Venous Circulating Tumor Cells in Resectable Pancreatic Cancer.
Choi YH; Hong TH; Yoon SB; Lee IS; Lee MA; Choi HJ; Choi MH; Jung ES
Biomedicines; 2022 May; 10(6):. PubMed ID: 35740311
[TBL] [Abstract][Full Text] [Related]
4. Portal Venous Circulating Tumor Cells Undergoing Epithelial-Mesenchymal Transition Exhibit Distinct Clinical Significance in Pancreatic Ductal Adenocarcinoma.
Pan Y; Li D; Yang J; Wang N; Xiao E; Tao L; Ding X; Sun P; Li D
Front Oncol; 2021; 11():757307. PubMed ID: 34778073
[TBL] [Abstract][Full Text] [Related]
5. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound.
Catenacci DV; Chapman CG; Xu P; Koons A; Konda VJ; Siddiqui UD; Waxman I
Gastroenterology; 2015 Dec; 149(7):1794-1803.e4. PubMed ID: 26341722
[TBL] [Abstract][Full Text] [Related]
6. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
7. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma.
White MG; Lee A; Vicente D; Hall C; Kim MP; Katz MHG; Lee JE; Ikoma N; Lucci A; Tzeng CD
Ann Surg Oncol; 2021 Aug; 28(8):4615-4622. PubMed ID: 33415562
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma.
Vicente D; Lee AJ; Hall CS; Lucci A; Lee JE; Kim MP; Katz MHG; Hurd MW; Maitra A; Rhim Md AD; Tzeng CD
J Surg Res; 2019 Nov; 243():90-99. PubMed ID: 31170555
[TBL] [Abstract][Full Text] [Related]
9. Portal vein-circulating tumor cells predict liver metastases in patients with resectable pancreatic cancer.
Bissolati M; Sandri MT; Burtulo G; Zorzino L; Balzano G; Braga M
Tumour Biol; 2015 Feb; 36(2):991-6. PubMed ID: 25318603
[TBL] [Abstract][Full Text] [Related]
10. Microfluidic Isolation of Circulating Tumor Cells and Cancer Stem-Like Cells from Patients with Pancreatic Ductal Adenocarcinoma.
Varillas JI; Zhang J; Chen K; Barnes II; Liu C; George TJ; Fan ZH
Theranostics; 2019; 9(5):1417-1425. PubMed ID: 30867841
[No Abstract] [Full Text] [Related]
11. Clinical Significance of Circulating Tumor Microemboli as a Prognostic Marker in Patients with Pancreatic Ductal Adenocarcinoma.
Chang MC; Chang YT; Chen JY; Jeng YM; Yang CY; Tien YW; Yang SH; Chen HL; Liang TY; Wang CF; Lee EY; Chang YC; Lee WH
Clin Chem; 2016 Mar; 62(3):505-13. PubMed ID: 26861552
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor Cells Predict Occult Metastatic Disease and Prognosis in Pancreatic Cancer.
Court CM; Ankeny JS; Sho S; Winograd P; Hou S; Song M; Wainberg ZA; Girgis MD; Graeber TG; Agopian VG; Tseng HR; Tomlinson JS
Ann Surg Oncol; 2018 Apr; 25(4):1000-1008. PubMed ID: 29442211
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications and perspectives of portal venous circulating tumor cells in pancreatic cancer.
Ko SW; Yoon SB
World J Gastrointest Oncol; 2023 Apr; 15(4):632-643. PubMed ID: 37123055
[TBL] [Abstract][Full Text] [Related]
14. A High Circulating Tumor Cell Count in Portal Vein Predicts Liver Metastasis From Periampullary or Pancreatic Cancer: A High Portal Venous CTC Count Predicts Liver Metastases.
Tien YW; Kuo HC; Ho BI; Chang MC; Chang YT; Cheng MF; Chen HL; Liang TY; Wang CF; Huang CY; Shew JY; Chang YC; Lee EY; Lee WH
Medicine (Baltimore); 2016 Apr; 95(16):e3407. PubMed ID: 27100430
[TBL] [Abstract][Full Text] [Related]
15. High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery.
Buscail E; Alix-Panabières C; Quincy P; Cauvin T; Chauvet A; Degrandi O; Caumont C; Verdon S; Lamrissi I; Moranvillier I; Buscail C; Marty M; Laurent C; Vendrely V; Moreau-Gaudry F; Bedel A; Dabernat S; Chiche L
Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31717747
[TBL] [Abstract][Full Text] [Related]
16. Endoscopic Ultrasound-Guided Acquisition of Portal Venous Circulating Tumor Cells as a Potential Diagnostic and Prognostic Tool for Pancreatic Cancer.
Zhang Y; Su H; Wang H; Xu C; Zhou S; Zhao J; Shen S; Xu G; Wang L; Zou X; Zhang S; Lv Y
Cancer Manag Res; 2021; 13():7649-7661. PubMed ID: 34675662
[TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma.
Torphy RJ; Tignanelli CJ; Kamande JW; Moffitt RA; Herrera Loeza SG; Soper SA; Yeh JJ
PLoS One; 2014; 9(2):e89474. PubMed ID: 24586805
[TBL] [Abstract][Full Text] [Related]
18. Phenotypic characteristics of circulating tumor cells and predictive impact for efficacy of chemotherapy in patients with pancreatic cancer: a prospective study.
Lee HS; Jung EH; Shin H; Park CS; Park SB; Jung DE; Leem G; Kim SJ; Jo JH; Chung MJ; Park JY; Bang S; Park SW; Song SY
Front Oncol; 2023; 13():1206565. PubMed ID: 37736542
[TBL] [Abstract][Full Text] [Related]
19. Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis of hepatocellular carcinoma after curative resection.
Sun YF; Xu Y; Yang XR; Guo W; Zhang X; Qiu SJ; Shi RY; Hu B; Zhou J; Fan J
Hepatology; 2013 Apr; 57(4):1458-68. PubMed ID: 23175471
[TBL] [Abstract][Full Text] [Related]
20. Serum CA19-9 as a marker of circulating tumor cells in first reflux blood of colorectal cancer patients.
Zhao JX; Liu LR; Yang XY; Liu F; Zhang ZG
Oncotarget; 2017 Sep; 8(40):67918-67932. PubMed ID: 28978084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
